Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM-101 in peripheral tinnitus (AMPACT2)
NCT02040207Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Jun 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gacyclidine in tinnitus, sponsored by Altamira Therapeutics. Primary endpoint: Hearing threshold at Day 203. Started Jun 2014; status: completed.
02
Drugs
gacyclidine
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT02040207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040207.